Arrotex bolsters respiratory portfolio with new Boehringer Ingelheim partnership
Media Release
February 6, 2020
Arrotex Pharmaceuticals Pty Ltd is today announcing a strategic partnership with Boehringer Ingelheim Pty Ltd for the exclusive Australian reseller rights to respiratory products* Spiriva® (tiotropium 18 micrograms powder for inhalation) and Spiriva® HandiHaler®.
Following the 2019 merger of Apotex Australia and Arrow Pharmaceuticals, the combined Arrotex entity now promotes GSK’s Seretide®, Pavtide® (Seretide® authorised generic), Flixotide® and Ventolin® CFC Inhaler brands, along with AstraZeneca’s respiratory brands Symbicort® Turbuhaler®, Symbicort® Rapihaler®, Pulmicort®, Omnaris®, Alvesco®, Bricanyl® and Oxis®.
Arrotex is committed to creating value for Australian community pharmacy. Through innovative partnerships, such as the Boehringer Ingelheim arrangement, Arrotex provides unique branded portfolio offerings for pharmacy to unlock additional revenue.
The partnership with Boehringer Ingelheim will take effect from 10 February 2020 and Apotex and Arrow will soon contact pharmacies with details of commercial arrangements.
Source: Viva Communications.
